Bellerophon Therapeutics

OverviewSuggest Edit

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. Its product candidates are INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and in Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis.
TypePublic
Founded2009
HQWarren, US
Websitebellerophon.com

Latest Updates

Employees (est.) (Dec 2018)17(-15%)
Share Price (Nov 2020)$8.5 (-2%)
Cybersecurity ratingCMore

Key People/Management at Bellerophon Therapeutics

Jonathan Peacock

Jonathan Peacock

Chairman
Assaf Korner

Assaf Korner

CFO
Martin Dekker

Martin Dekker

Vice President, Engineering and Manufacturing
Amy Edmonds

Amy Edmonds

Vice President, Clinical Operations and Administration
Show more

Bellerophon Therapeutics Office Locations

Bellerophon Therapeutics has an office in Warren
Warren, US (HQ)
184 Liberty Corner Rd #302
Show all (1)

Bellerophon Therapeutics Financials and Metrics

Bellerophon Therapeutics Revenue

USD

Net income (Q3, 2020)

(7.9m)

EBIT (Q3, 2020)

(8.3m)

Market capitalization (17-Nov-2020)

81.1m

Closing stock price (17-Nov-2020)

8.5

Cash (30-Sept-2020)

54.0m

EV

29.0m
Bellerophon Therapeutics's current market capitalization is $81.1 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

14.9m7.1m6.7m7.6m6.4m

R&D expense

33.4m16.7m17.9m20.3m11.0m

Operating expense total

48.2m23.8m24.6m27.9m17.5m

EBIT

(46.6m)(23.8m)(24.6m)(27.9m)(17.5m)
Quarterly
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

6.3m14.5m28.8m16.6m9.9m

Prepaid Expenses

5.4m3.4m650.0k405.0k

Current Assets

29.5m26.5m35.6m17.4m10.4m

PP&E

1.8m1.4m1.0m664.0k316.0k
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(46.5m)(23.8m)(54.8m)2.8m(13.3m)

Depreciation and Amortization

373.0k362.0k348.0k

Cash From Operating Activities

(46.3m)(17.2m)(15.7m)(15.5m)(12.9m)

Purchases of PP&E

(458.0k)(22.0k)
USDQ1, 2015

Financial Leverage

1.2 x
Show all financial metrics

Bellerophon Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

77/100

SecurityScorecard logo

Bellerophon Therapeutics Online and Social Media Presence

Embed Graph

Bellerophon Therapeutics News and Updates

Bellerophon Therapeutics Announces Closing of $43.7 Million Public Offering of Common Stock and Concurrent Registered Direct Offering and Full Exercise of Option to Purchase Additional Shares

WARREN, N.J., May 22, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced the closing of its previously announced public offering and concurrent registered direct offering (the “Offerings”) for gross proceeds of approximately $43.…

Bellerophon Therapeutics Submits Investigational New Drug Application to Study INOpulse® Inhaled Nitric Oxide Therapy for the Treatment of COVID-19

IND Submission Follows Completed Treatment of Several COVID-19 Patients with INOpulse Under FDA Authorized Emergency Expanded Access Program IND Submission Follows Completed Treatment of Several COVID-19 Patients with INOpulse Under FDA Authorized Emergency Expanded Access Program

Bellerophon Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

WARREN, N.J., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an unde…

Bellerophon Therapeutics Blogs

Hello world!

Welcome to WordPress. This is your first post. Edit or delete it, then start blogging! The post Hello world! appeared first on bellerophon.

Bellerophon Therapeutics Frequently Asked Questions

  • When was Bellerophon Therapeutics founded?

    Bellerophon Therapeutics was founded in 2009.

  • Who are Bellerophon Therapeutics key executives?

    Bellerophon Therapeutics's key executives are Jonathan Peacock, Assaf Korner and Martin Dekker.

  • How many employees does Bellerophon Therapeutics have?

    Bellerophon Therapeutics has 17 employees.

  • Who are Bellerophon Therapeutics competitors?

    Competitors of Bellerophon Therapeutics include Cellestia Biotech, Deciphera Pharmaceuticals and Synthorx.

  • Where is Bellerophon Therapeutics headquarters?

    Bellerophon Therapeutics headquarters is located at 184 Liberty Corner Rd #302, Warren.

  • Where are Bellerophon Therapeutics offices?

    Bellerophon Therapeutics has an office in Warren.

  • How many offices does Bellerophon Therapeutics have?

    Bellerophon Therapeutics has 1 office.